諾誠健華(688428.SH):子公司與Prolium 簽訂CD20×CD3雙特異性抗體(ICP-B02/CM355)許可協議
格隆匯1月20日丨諾誠健華(688428.SH)公佈,公司的子公司北京諾誠健華醫藥科技有限公司(以下簡稱“北京諾誠健華”)、康諾亞生物醫藥科技(成都)有限公司(以下簡稱“成都康諾亞”)、北京天諾健成醫藥科技有限公司(以下簡稱“天諾健成”,由北京諾誠健華和成都康諾亞各持股50%股權)、與Prolium
BioscienceInc.(以下簡稱“Prolium”)簽訂獨佔許可協議(以下簡稱“協議”),授予Prolium在全球非腫瘤領域以及除亞洲以外的全球腫瘤領域,開展ICP-B02(CM355),即CD20×CD3雙特異性抗體的開發、註冊、生產和商業化的獨佔權利。
根據協議,北京諾誠健華和成都康諾亞將按各50%的比例合計獲得1,750萬美元的首期及近期付款,並根據特定臨牀、監管及商業化里程碑的實現情況,有權合計獲得最高5.025億美元的額外里程碑付款。同時,雙方還將獲得未來產品淨銷售額的分層特許權使用費,且作為本次交易對價的一部分,北京諾誠健華和成都康諾亞(或其指定機構)還將獲得Prolium的少數股權。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.